Recent advances in the clinical management of end-stage pediatric pulmonary hypertension
Rattachement africain : se, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE OF REVIEW: This review aims to give an overview of recent advances in the clinical management of children <18 years of age with end-stage pulmonary hypertension refractory to conventional medical therapy. RECENT FINDINGS/SUMMARY: The increased awareness and characterization of pediatric pulmonary vascular disease has amounted more data toward creating an accurate, and comprehensive, risk prediction tool. This underscores the importance of serial outpatient re-assessment, as early consideration of advanced pharmaceutical and interventional therapies, as well as lung transplantation, improves outcomes in children. Despite the emergence and approval of new therapies against pulmonary hypertension in adults, pediatric-specific complications have not yet been adequately explored. It is, however, encouraging that several trials are ongoing to address this issue. Interventional strategies to unload the right ventricle are increasingly being utilized, although evidence remains scarce in this area. Extra-corporeal membrane oxygenation may, in addition to being a bridge to lung transplantation in well-selected patients, be considered as a bridge to catheter-based or surgical interventions. Management of pediatric right ventricular failure in the setting of advanced pulmonary hypertension is a truly complex clinical challenge at the intersection of cardiac, vascular and respiratory physiology and requires careful integration of invasive hemodynamic assessment, pulmonary vasodilator therapy, ventilatory strategy, and timely consideration of mechanical circulatory support.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Recent advances in the clinical management of end-stage pediatric pulmonary hypertension
- Date Crossref
- 20/05/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Wallenberg Wood Science Center pays non établi dans la noticeStructure de recherche
-
Skåne University Hospital The Pediatric Heart Center pays non établi dans la noticeÉtablissement de santé
-
Palo Alto University pays non établi dans la noticeUniversité ou école supérieure
-
Stanford Medicine pays non établi dans la noticeÉtablissement de santé
-
Stanford University Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
-
Lund University Department of Experimental Medical Science and The Wallenberg Center for Molecular Medicine pays non établi dans la noticeUniversité ou école supérieure
Wallenberg Wood Science Center, The Pediatric Heart Center — Skåne University Hospital et Palo Alto University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.